Association of serum vitamin C with liver fibrosis in adults with nonalcoholic fatty liver disease

References

• Younossi ZM. Non-alcoholic fatty liver disease – a global public health perspective. J Hepatol. 2019;70(3):531–544.
   PubMed Web of Science ®Google Scholar
• Parola M, Pinzani M. Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med. 2019;65:37–55.
   PubMed Web of Science ®Google Scholar
• Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol. 2011;6:425–456.
   PubMed Web of Science ®Google Scholar
• Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020;9(4):875.
   PubMed Web of Science ®Google Scholar
• Salomone F, Li VG, Rosso C, et al. Unconjugated bilirubin, a potent endogenous antioxidant, is decreased in patients with non-alcoholic steatohepatitis and advanced fibrosis. J Gastroenterol Hepatol. 2013;28(7):1202–1208.
   PubMed Web of Science ®Google Scholar
• Bellanti F, Villani R, Facciorusso A, et al. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis. Free Radic Biol Med. 2017;111:173–185.
   PubMed Web of Science ®Google Scholar
• Weiskirchen R, Weiskirchen S, Tacke F. Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts. F1000Res. 2018;7:921.
   Google Scholar
• Ipsen DH, Tveden-Nyborg P, Lykkesfeldt J. Does vitamin C deficiency promote fatty liver disease development? Nutrients. 2014;6(12):5473–5499.
   PubMed Web of Science ®Google Scholar
• Padayatty SJ, Katz A, Wang Y, et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr. 2003;22(1):18–35.
   PubMed Web of Science ®Google Scholar
• Abe R, Masroor A, Khorochkov A, et al. The role of vitamins in non-alcoholic fatty liver disease: a systematic review. Cureus. 2021;13(8):e16855.
   PubMed Web of Science ®Google Scholar
• Ivancovsky-Wajcman D, Fliss-Isakov N, Salomone F, et al. Dietary vitamin E and C intake is inversely associated with the severity of nonalcoholic fatty liver disease. Dig Liver Dis. 2019;51(12):1698–1705.
   PubMedGoogle Scholar
• Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(5):1264–1281.
   PubMed Web of Science ®Google Scholar
• Pu K, Wang Y, Bai S, et al. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis. BMC Gastroenterol. 2019;19(1):51.
   PubMed Web of Science ®Google Scholar
• Chen TC, Clark J, Riddles MK, et al. National Health and Nutrition Examination Survey, 2015–2018: sample design and estimation procedures. Vital Health Stat. 2020;2(184):1–35.
   Google Scholar
• Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022–1030.
   PubMed Web of Science ®Google Scholar
• EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol. 2021;75(3):659–689.
   PubMed Web of Science ®Google Scholar
• Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66(5):1486–1501.
   PubMed Web of Science ®Google Scholar
• Tsochatzis EA, Gurusamy KS, Ntaoula S, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol. 2011;54(4):650–659.
   PubMed Web of Science ®Google Scholar
• Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717–1730.
   PubMed Web of Science ®Google Scholar
• Jiang W, Huang S, Teng H, et al. Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis. BMJ Open. 2018;8(8):e21787.
   Web of Science ®Google Scholar
• Menke A, Casagrande S, Geiss L, et al. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA. 2015;314(10):1021–1029.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–2023.
   PubMed Web of Science ®Google Scholar
• Urtasun R, Conde DLRL, Nieto N. Oxidative and nitrosative stress and fibrogenic response. Clin Liver Dis. 2008;12(4):769–790.
   PubMed Web of Science ®Google Scholar
• Bae M, Park YK, Lee JY. Food components with antifibrotic activity and implications in prevention of liver disease. J Nutr Biochem. 2018;55:1–11.
   PubMed Web of Science ®Google Scholar
• Gambino R, Musso G, Cassader M. Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. Antioxid Redox Signal. 2011;15(5):1325–1365.
   PubMed Web of Science ®Google Scholar
• Raza S, Tewari A, Rajak S, et al. Vitamins and non-alcoholic fatty liver disease: a molecular insight. Liver Res. 2021;5(2):62–71.
   PubMedGoogle Scholar
• Lee H, Ahn J, Shin SS, et al. Ascorbic acid inhibits visceral obesity and nonalcoholic fatty liver disease by activating peroxisome proliferator-activated receptor α in high-fat-diet-fed C57BL/6J mice. Int J Obes. 2019;43(8):1620–1630.
   Web of Science ®Google Scholar
• Zeng Q, Zhao L, Meng C, et al. Prophylactic and therapeutic effects of different doses of vitamin C on high-fat-diet-induced non-alcoholic fatty liver disease in mice. Biomed Pharmacother. 2020;131:110792.
   PubMed Web of Science ®Google Scholar
• Rezazadeh A, Yazdanparast R, Molaei M. Amelioration of diet-induced nonalcoholic steatohepatitis in rats by Mn–salen complexes via reduction of oxidative stress. J Biomed Sci. 2012;19:26.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Torgerson S, Hayashi P, et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98(11):2485–2490.
   PubMed Web of Science ®Google Scholar
• Nobili V, Manco M, Devito R, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology. 2008;48(1):119–128.
   PubMed Web of Science ®Google Scholar
• Zhang ZC, Liu Y, Xiao LL, et al. Upregulation of miR-125b by estrogen protects against non-alcoholic fatty liver in female mice. J Hepatol. 2015;63(6):1466–1475.
   PubMed Web of Science ®Google Scholar
• Ezhilarasan D. Critical role of estrogen in the progression of chronic liver diseases. Hepatobiliary Pancreat Dis Int. 2020;19(5):429–434.
   PubMed Web of Science ®Google Scholar
• Wei J, Lei GH, Fu L, et al. Association between dietary vitamin C intake and non-alcoholic fatty liver disease: a cross-sectional study among middle-aged and older adults. PLOS One. 2016;11(1):e147985.
   PubMed Web of Science ®Google Scholar
• Font-Burgada J, Sun B, Karin M. Obesity and cancer: the oil that feeds the flame. Cell Metab. 2016;23(1):48–62.
   PubMed Web of Science ®Google Scholar
• Chiang DJ, Pritchard MT, Nagy LE. Obesity, diabetes mellitus, and liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2011;300(5):G697–G702.
   PubMed Web of Science ®Google Scholar
• Thomas-Valdes S, Tostes M, Anunciacao PC, et al. Association between vitamin deficiency and metabolic disorders related to obesity. Crit Rev Food Sci Nutr. 2017;57(15):3332–3343.
   PubMed Web of Science ®Google Scholar
• Manna P, Jain SK. Obesity, oxidative stress, adipose tissue dysfunction, and the associated health risks: causes and therapeutic strategies. Metab Syndr Relat Disord. 2015;13(10):423–444.
   PubMed Web of Science ®Google Scholar
• Sirli R, Sporea I. Controlled attenuation parameter for quantification of steatosis: which cut-offs to use? Can J Gastroenterol Hepatol. 2021;2021:6662760.
   PubMed Web of Science ®Google Scholar